tetano
Editor, Senior Moderator
Front Immunol
. 2022 Dec 21;13:1062210.
doi: 10.3389/fimmu.2022.1062210. eCollection 2022.
In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant
Natalie Heinen[SUP] 1 [/SUP], Corinna Sophie Marheinecke[SUP] 1 [/SUP], Clara Bessen[SUP] 2 [/SUP], Arturo Blazquez-Navarro[SUP] 3 4 [/SUP], Toralf Roch[SUP] 3 4 [/SUP], Ulrik Stervbo[SUP] 3 [/SUP], Moritz Anft[SUP] 3 [/SUP], Carlos Plaza-Sirvent[SUP] 2 [/SUP], Sandra Busse[SUP] 2 [/SUP], Mara Klöhn[SUP] 1 [/SUP], Jil Schrader[SUP] 1 [/SUP], Elena Vidal Blanco[SUP] 1 [/SUP], Doris Urlaub[SUP] 5 [/SUP], Carsten Watzl[SUP] 5 [/SUP], Markus Hoffmann[SUP] 6 [/SUP], Stefan Pöhlmann[SUP] 6 [/SUP], Matthias Tenbusch[SUP] 7 [/SUP], Eike Steinmann[SUP] 1 [/SUP], Daniel Todt[SUP] 1 8 [/SUP], Carsten Hagenbeck[SUP] 9 [/SUP], Gert Zimmer[SUP] 9 10 [/SUP], Wolfgang Ekkehard Schmidt[SUP] 11 [/SUP], Daniel Robert Quast[SUP] 11 [/SUP], Nina Babel[SUP] 3 4 [/SUP], Ingo Schmitz[SUP] 2 [/SUP], Stephanie Pfänder[SUP] 1 [/SUP]
Affiliations
Abstract
With the emergence of novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Variants of Concern (VOCs), vaccination studies that elucidate the efficiency and effectiveness of a vaccination campaign are critical to assess the durability and the protective immunity provided by vaccines. SARS-CoV-2 vaccines have been found to induce robust humoral and cell-mediated immunity in individuals vaccinated with homologous vaccination regimens. Recent studies also suggest improved immune response against SARS-CoV-2 when heterologous vaccination strategies are employed. Yet, few data exist on the extent to which heterologous prime-boost-boost vaccinations with two different vaccine platforms have an impact on the T cell-mediated immune responses with a special emphasis on the currently dominantly circulating Omicron strain. In this study, we collected serum and peripheral blood mononuclear cells (PBMCs) from 57 study participants of median 35-year old's working in the health care field, who have received different vaccination regimens. Neutralization assays revealed robust but decreased neutralization of Omicron VOC, including BA.1 and BA.4/5, compared to WT SARS-CoV-2 in all vaccine groups and increased WT SARS-CoV-2 binding and neutralizing antibodies titers in homologous mRNA prime-boost-boost study participants. By investigating cytokine production, we found that homologous and heterologous prime-boost-boost-vaccination induces a robust cytokine response of CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cells. Collectively, our results indicate robust humoral and T cell mediated immunity against Omicron in homologous and heterologous prime-boost-boost vaccinated study participants, which might serve as a guide for policy decisions.
Keywords: COVID-19; SARS-CoV-2; immunity; omicron; vaccine.
. 2022 Dec 21;13:1062210.
doi: 10.3389/fimmu.2022.1062210. eCollection 2022.
In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant
Natalie Heinen[SUP] 1 [/SUP], Corinna Sophie Marheinecke[SUP] 1 [/SUP], Clara Bessen[SUP] 2 [/SUP], Arturo Blazquez-Navarro[SUP] 3 4 [/SUP], Toralf Roch[SUP] 3 4 [/SUP], Ulrik Stervbo[SUP] 3 [/SUP], Moritz Anft[SUP] 3 [/SUP], Carlos Plaza-Sirvent[SUP] 2 [/SUP], Sandra Busse[SUP] 2 [/SUP], Mara Klöhn[SUP] 1 [/SUP], Jil Schrader[SUP] 1 [/SUP], Elena Vidal Blanco[SUP] 1 [/SUP], Doris Urlaub[SUP] 5 [/SUP], Carsten Watzl[SUP] 5 [/SUP], Markus Hoffmann[SUP] 6 [/SUP], Stefan Pöhlmann[SUP] 6 [/SUP], Matthias Tenbusch[SUP] 7 [/SUP], Eike Steinmann[SUP] 1 [/SUP], Daniel Todt[SUP] 1 8 [/SUP], Carsten Hagenbeck[SUP] 9 [/SUP], Gert Zimmer[SUP] 9 10 [/SUP], Wolfgang Ekkehard Schmidt[SUP] 11 [/SUP], Daniel Robert Quast[SUP] 11 [/SUP], Nina Babel[SUP] 3 4 [/SUP], Ingo Schmitz[SUP] 2 [/SUP], Stephanie Pfänder[SUP] 1 [/SUP]
Affiliations
- PMID: 36618413
- PMCID: PMC9811676
- DOI: 10.3389/fimmu.2022.1062210
Abstract
With the emergence of novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Variants of Concern (VOCs), vaccination studies that elucidate the efficiency and effectiveness of a vaccination campaign are critical to assess the durability and the protective immunity provided by vaccines. SARS-CoV-2 vaccines have been found to induce robust humoral and cell-mediated immunity in individuals vaccinated with homologous vaccination regimens. Recent studies also suggest improved immune response against SARS-CoV-2 when heterologous vaccination strategies are employed. Yet, few data exist on the extent to which heterologous prime-boost-boost vaccinations with two different vaccine platforms have an impact on the T cell-mediated immune responses with a special emphasis on the currently dominantly circulating Omicron strain. In this study, we collected serum and peripheral blood mononuclear cells (PBMCs) from 57 study participants of median 35-year old's working in the health care field, who have received different vaccination regimens. Neutralization assays revealed robust but decreased neutralization of Omicron VOC, including BA.1 and BA.4/5, compared to WT SARS-CoV-2 in all vaccine groups and increased WT SARS-CoV-2 binding and neutralizing antibodies titers in homologous mRNA prime-boost-boost study participants. By investigating cytokine production, we found that homologous and heterologous prime-boost-boost-vaccination induces a robust cytokine response of CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cells. Collectively, our results indicate robust humoral and T cell mediated immunity against Omicron in homologous and heterologous prime-boost-boost vaccinated study participants, which might serve as a guide for policy decisions.
Keywords: COVID-19; SARS-CoV-2; immunity; omicron; vaccine.